Inicio・Lista de Acciones・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Abierto

SectorSanidad

40.74 4.27

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

38.46

Máximo

40.47

Métricas clave
By Trading Economics
Ingresos	2.6M -79M
Ventas	-60K 15K
BPA	-1.18
Margen de beneficios	-524,566.667
Empleados	198
EBITDA	2.7M -78M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+45.76% upside

Dividendos
By Acuity
Próximas Ganancias	5 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	386M 3B
Apertura anterior	36.47
Cierre anterior	40.74

Noticias sobre sentimiento de mercado

By Acuity

50%

175 / 340 Clasificación en Healthcare

Celldex Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 ago 2026, 19:56 UTC

Celldex Therapeutics Inc shares are higher today, supported by overall market strength amid a decline in crude oil prices. No specific company news was identified.

3 ago 2026, 19:53 UTC

Celldex Therapeutics Inc. shares are lower as biotechnology stocks decline. The broader sector's weakness has influenced the stock's price action today.

31 jul 2026, 19:36 UTC

Celldex Therapeutics Inc. shares are lower today amid significant pressure on biotechnology stocks, with no specific company news identified to explain the decline.

30 jul 2026, 18:51 UTC

Celldex Therapeutics Inc is advancing during Thursday's session, moving higher alongside the broader market amid positive macroeconomic sentiment.

29 jul 2026, 20:03 UTC

Macro Event

News

Wells Fargo raised its price target on Celldex Therapeutics to $72, citing confidence in the company's growth prospects and promising pipeline. Shares are higher today.

28 jul 2026, 19:36 UTC

Shares of Celldex Therapeutics Inc. are lower today, continuing a decline since Monday's close, despite an earlier modest rebound from session lows.

27 jul 2026, 19:31 UTC

News

Celldex Therapeutics is higher today, bolstered by strong sentiment for its barzolvolimab program and successful Phase 3 enrollment for chronic spontaneous urticaria trials.

22 jul 2026, 20:01 UTC

Event

News

Social Media

Celldex Therapeutics is lower after discontinuing barzolvolimab development due to failed trial results. Wells Fargo lowered its price target to $48.

21 jul 2026, 23:01 UTC

Social Media

Event

News

Celldex Therapeutics shares fell in after-market hours following disappointing Phase 2 trial results for barzolvolimab, which failed to meet primary and secondary endpoints.

Comparación entre iguales

Cambio de precio

Celldex Therapeutics Inc previsión

Precio Objetivo

By TipRanks

45.76% repunte

Estimación a 12 Meses

Media 56.92 USD 45.76%

Máximo 100 USD

Mínimo 34 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Celldex Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

Comprar

Mantener

Vender

De acuerdo con 14 analistas que ofrecen calificaciones bursátiles a para Celldex Therapeutics Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

175 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.